Similar articles

• Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.

  Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML. Rustgi VK, et al. Aliment Pharmacol Ther. 2008 Mar 1;27(5):433-40. doi: 10.1111/j.1365-2036.2007.03587.x. Epub 2007 Dec 10. Aliment Pharmacol Ther. 2008. PMID: 18081737 Clinical Trial.
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Fried MW, et al. N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047. N Engl J Med. 2002. PMID: 12324553 Clinical Trial.
• Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

  Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. Lukasiewicz E, et al. Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505. Hepatology. 2007. PMID: 17187414 No abstract available.
• Current therapy for hepatitis C: pegylated interferon and ribavirin.

  McHutchison JG, Fried MW. McHutchison JG, et al. Clin Liver Dis. 2003 Feb;7(1):149-61. doi: 10.1016/s1089-3261(02)00077-6. Clin Liver Dis. 2003. PMID: 12691464 Review.
• Peginterferon and ribavirin for chronic hepatitis C.

  Hoofnagle JH, Seeff LB. Hoofnagle JH, et al. N Engl J Med. 2006 Dec 7;355(23):2444-51. doi: 10.1056/NEJMct061675. N Engl J Med. 2006. PMID: 17151366 Review. No abstract available.